In a report released yesterday, Kaveri Pohlman from BTIG maintained a Hold rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed yesterday at $1.34.
According to TipRanks, Pohlman is an analyst with an average return of -31.7% and a 15.53% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Seagen, Arcus Biosciences, and Genmab.
The word on The Street in general, suggests a Hold analyst consensus rating for Mersana Therapeutics with a $1.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.62 and a one-year low of $0.80. Currently, Mersana Therapeutics has an average volume of 2.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics (MRSN) Company Description:
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More on MRSN:
- Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
- Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
- Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
- Mersana Therapeutics says FDA lifts clinical hold on Phase 1 trial of XMT-2056
- Centessa adds April Dovholuk, Ellie Im to senior leadership team
